Heard on the Street: Johnson & Johnson seems to have perfected the art of the biotech deal, but there’s a catch

Partnership strategy has produced great pharma bargains—and left the company exposed.

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

Partnership strategy has produced great pharma bargains—and left the company exposed.

Palestinians use recycling as Israel’s restrictions trigger a trash crisis

Palestinians in the West Bank live amid garbage following Israeli restrictions. Two Palestinian entrepreneurs are trying…

Renewable energy is overtaking traditional power projects across Africa, industry leaders say

Africa’s energy sector is rapidly shifting toward solar and wind power and battery storage as governments…

Renewable energy is overtaking traditional power projects in Africa

Africa’s energy sector is rapidly shifting toward solar and wind power and battery storage as governments…

Biotech Investors Are Tuning Out the MAHA Chaos

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

Biotech Investors Are Tuning Out the MAHA Chaos

The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.

How one Oregon city has raised a billion dollars for climate change

The Portland Clean Energy Fund has raised a billion dollars for climate change action via a…

Zambia Helped Chinese Miner Cover Up Pollution Disaster, House Committee Finds

Toxic waste inundated homes and fields in a spill over a year ago. Zambia is relying…

Ligand Pharmaceuticals said it has reached a deal to acquire Xoma Royalty, a company that invests in a range of biotech firms, for around $740 million

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect…